



Sanofi statement on impact of COVID-19 on UK supply of medicines

Following the pandemic alert from the World Health Organisation (WHO), Sanofi understands that patients may be concerned about the availability of their medicine. Sanofi has, for several weeks, activated a Global Crisis committee and a local crisis team in the UK to ensure continuity of supply of medicines. These committees have worked closely with our suppliers in China, India and the rest of the world to ensure we can continue to manufacture and deliver the important medicines patients rely on.

At the same time, we are committed to ensuring the safety and health of our employees around the world, their families, and our communities.

To date, there has not been any impact on our supply and manufacturing operations and, at this time, Sanofi does not anticipate shortages for patients resulting from the COVID-19 situation.

Patients with an immunological condition or who are taking a medicine which has an immunosuppressive effect and are concerned about the impact of COVID-19 are advised to speak to their health care professional as soon as possible.

Decisions on whether Sanofi-led events or meetings will go ahead are being made by the relevant teams.

Sanofi advocates that people follow the steps outlined by the UK Government, NHS England and Public Health England in order to protect themselves and others from the virus.